Regorafenib-induced exacerbation of chronic immune thrombocytopenic purpura in remission: A case report

Regorafenib is an oral multi-kinase inhibitor which targets tumor angiogenesis, the tumor microenvironment and oncogenesis. Based on this mode of action, regorafenib has a broad spectrum of toxicities. However, at present, few reports have focused on autoimmune adverse events. We report a first case...

Descripción completa

Detalles Bibliográficos
Autores principales: Kimbara, Shiro, Imamura, Yoshinori, Yakushijin, Kimikazu, Higashime, Ako, Koyama, Taiji, Fujishima, Yoshimi, Funakoshi, Yohei, Toyoda, Masanori, Kiyota, Naomi, Matsuoka, Hiroshi, Minami, Hironobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783712/
https://www.ncbi.nlm.nih.gov/pubmed/33414911
http://dx.doi.org/10.3892/mco.2020.2192
_version_ 1783632165315018752
author Kimbara, Shiro
Imamura, Yoshinori
Yakushijin, Kimikazu
Higashime, Ako
Koyama, Taiji
Fujishima, Yoshimi
Funakoshi, Yohei
Toyoda, Masanori
Kiyota, Naomi
Matsuoka, Hiroshi
Minami, Hironobu
author_facet Kimbara, Shiro
Imamura, Yoshinori
Yakushijin, Kimikazu
Higashime, Ako
Koyama, Taiji
Fujishima, Yoshimi
Funakoshi, Yohei
Toyoda, Masanori
Kiyota, Naomi
Matsuoka, Hiroshi
Minami, Hironobu
author_sort Kimbara, Shiro
collection PubMed
description Regorafenib is an oral multi-kinase inhibitor which targets tumor angiogenesis, the tumor microenvironment and oncogenesis. Based on this mode of action, regorafenib has a broad spectrum of toxicities. However, at present, few reports have focused on autoimmune adverse events. We report a first case of regorafenib-induced exacerbation of chronic immune thrombocytopenic purpura in remission during treatment for the patients with heavily treated advanced colorectal cancer. This case report highlights the need for caution with regard to regorafenib treatment in patients with cancer with concomitant immune thrombocytopenic purpura.
format Online
Article
Text
id pubmed-7783712
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-77837122021-01-06 Regorafenib-induced exacerbation of chronic immune thrombocytopenic purpura in remission: A case report Kimbara, Shiro Imamura, Yoshinori Yakushijin, Kimikazu Higashime, Ako Koyama, Taiji Fujishima, Yoshimi Funakoshi, Yohei Toyoda, Masanori Kiyota, Naomi Matsuoka, Hiroshi Minami, Hironobu Mol Clin Oncol Articles Regorafenib is an oral multi-kinase inhibitor which targets tumor angiogenesis, the tumor microenvironment and oncogenesis. Based on this mode of action, regorafenib has a broad spectrum of toxicities. However, at present, few reports have focused on autoimmune adverse events. We report a first case of regorafenib-induced exacerbation of chronic immune thrombocytopenic purpura in remission during treatment for the patients with heavily treated advanced colorectal cancer. This case report highlights the need for caution with regard to regorafenib treatment in patients with cancer with concomitant immune thrombocytopenic purpura. D.A. Spandidos 2021-02 2020-12-16 /pmc/articles/PMC7783712/ /pubmed/33414911 http://dx.doi.org/10.3892/mco.2020.2192 Text en Copyright: © Kimbara et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Kimbara, Shiro
Imamura, Yoshinori
Yakushijin, Kimikazu
Higashime, Ako
Koyama, Taiji
Fujishima, Yoshimi
Funakoshi, Yohei
Toyoda, Masanori
Kiyota, Naomi
Matsuoka, Hiroshi
Minami, Hironobu
Regorafenib-induced exacerbation of chronic immune thrombocytopenic purpura in remission: A case report
title Regorafenib-induced exacerbation of chronic immune thrombocytopenic purpura in remission: A case report
title_full Regorafenib-induced exacerbation of chronic immune thrombocytopenic purpura in remission: A case report
title_fullStr Regorafenib-induced exacerbation of chronic immune thrombocytopenic purpura in remission: A case report
title_full_unstemmed Regorafenib-induced exacerbation of chronic immune thrombocytopenic purpura in remission: A case report
title_short Regorafenib-induced exacerbation of chronic immune thrombocytopenic purpura in remission: A case report
title_sort regorafenib-induced exacerbation of chronic immune thrombocytopenic purpura in remission: a case report
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783712/
https://www.ncbi.nlm.nih.gov/pubmed/33414911
http://dx.doi.org/10.3892/mco.2020.2192
work_keys_str_mv AT kimbarashiro regorafenibinducedexacerbationofchronicimmunethrombocytopenicpurpurainremissionacasereport
AT imamurayoshinori regorafenibinducedexacerbationofchronicimmunethrombocytopenicpurpurainremissionacasereport
AT yakushijinkimikazu regorafenibinducedexacerbationofchronicimmunethrombocytopenicpurpurainremissionacasereport
AT higashimeako regorafenibinducedexacerbationofchronicimmunethrombocytopenicpurpurainremissionacasereport
AT koyamataiji regorafenibinducedexacerbationofchronicimmunethrombocytopenicpurpurainremissionacasereport
AT fujishimayoshimi regorafenibinducedexacerbationofchronicimmunethrombocytopenicpurpurainremissionacasereport
AT funakoshiyohei regorafenibinducedexacerbationofchronicimmunethrombocytopenicpurpurainremissionacasereport
AT toyodamasanori regorafenibinducedexacerbationofchronicimmunethrombocytopenicpurpurainremissionacasereport
AT kiyotanaomi regorafenibinducedexacerbationofchronicimmunethrombocytopenicpurpurainremissionacasereport
AT matsuokahiroshi regorafenibinducedexacerbationofchronicimmunethrombocytopenicpurpurainremissionacasereport
AT minamihironobu regorafenibinducedexacerbationofchronicimmunethrombocytopenicpurpurainremissionacasereport

Ejemplares similares